Resources

Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients

Cancer chemotherapy and pharmacology, Vol. 89, Issue 3, Pages 393-400, 2022

PMID: 35157101

Pediatric acute lymphoblastic leukemia (pALL) patients have better overall survival and methotrexate (MTX) is an effective drug used in their treatment. However, the treatment-related adverse effects (TRAEs) have a bigger impact on the therapy. In this study, we have evaluated the association of polymorphisms in genes encoding proteins engaged in MTX metabolism, and the cytogenetic aberrations with TRAEs.

Read More

  https://pubmed.ncbi.nlm.nih.gov/35157101/

 

Considering Genomic Research?

    Fields marked in * is mandatory to fill
     
     
     

    2024 © MedGenome • All Rights Reserved
    Request a Quote